In this study we show that in patients with chronic csDMARD-unresponsive rheumatoid arthritis, tofacitinib suppresses multiple JAK-STAT pathways in vivo by decreasing both constitutive and cytokine-induced STAT phosphorylation in circulating leukocytes. The gene discussed is SOAT1; the disease is rheumatoid arthritis.